These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 20079528)

  • 1. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
    Cannon CP; Harrington RA; James S; Ardissino D; Becker RC; Emanuelsson H; Husted S; Katus H; Keltai M; Khurmi NS; Kontny F; Lewis BS; Steg PG; Storey RF; Wojdyla D; Wallentin L;
    Lancet; 2010 Jan; 375(9711):283-93. PubMed ID: 20079528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    Wallentin L; Becker RC; Budaj A; Cannon CP; Emanuelsson H; Held C; Horrow J; Husted S; James S; Katus H; Mahaffey KW; Scirica BM; Skene A; Steg PG; Storey RF; Harrington RA; ; Freij A; Thorsén M
    N Engl J Med; 2009 Sep; 361(11):1045-57. PubMed ID: 19717846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
    Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
    Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.
    Levin LÅ; Wallentin L; Bernfort L; Andersson D; Storey RF; Bergström G; Lamm CJ; Janzon M; Kaul P
    Value Health; 2013 Jun; 16(4):574-80. PubMed ID: 23796291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
    Varenhorst C; Alström U; Scirica BM; Hogue CW; Åsenblad N; Storey RF; Steg PG; Horrow J; Mahaffey KW; Becker RC; James S; Cannon CP; Brandrup-Wognsen G; Wallentin L; Held C
    J Am Coll Cardiol; 2012 Oct; 60(17):1623-30. PubMed ID: 23021325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
    Becker RC; Bassand JP; Budaj A; Wojdyla DM; James SK; Cornel JH; French J; Held C; Horrow J; Husted S; Lopez-Sendon J; Lassila R; Mahaffey KW; Storey RF; Harrington RA; Wallentin L
    Eur Heart J; 2011 Dec; 32(23):2933-44. PubMed ID: 22090660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    James S; Budaj A; Aylward P; Buck KK; Cannon CP; Cornel JH; Harrington RA; Horrow J; Katus H; Keltai M; Lewis BS; Parikh K; Storey RF; Szummer K; Wojdyla D; Wallentin L
    Circulation; 2010 Sep; 122(11):1056-67. PubMed ID: 20805430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
    Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
    J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
    Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
    Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
    J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
    Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
    Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
    Armstrong PW; Siha H; Fu Y; Westerhout CM; Steg PG; James SK; Storey RF; Horrow J; Katus H; Clemmensen P; Harrington RA; Wallentin L
    Circulation; 2012 Jan; 125(3):514-21. PubMed ID: 22179530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
    Mehta SR; Tanguay JF; Eikelboom JW; Jolly SS; Joyner CD; Granger CB; Faxon DP; Rupprecht HJ; Budaj A; Avezum A; Widimsky P; Steg PG; Bassand JP; Montalescot G; Macaya C; Di Pasquale G; Niemela K; Ajani AE; White HD; Chrolavicius S; Gao P; Fox KA; Yusuf S;
    Lancet; 2010 Oct; 376(9748):1233-43. PubMed ID: 20817281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.